Mycobacterium, E.coli, S.aureus, Bacillus susceptibility to Amoxicillin/Clavulanic acid fact check
“to susceptibility of Mycobacterium species, E.coli, S.aureus, Bacillus species to Amoycillin/Clauulonic acid”
Summary
Current scientific literature and regulatory resources do not provide any data on the susceptibility of Mycobacterium species, *E. coli*, *S. aureus*, or *Bacillus* species to Amoycillin or Clauulonic acid. The available sources discuss other antibiotics and general susceptibility testing but contain no evidence confirming effectiveness of these two agents against the listed bacteria.
Sources 60 searched
- Bacterial persisters: molecular mechanisms and therapeutic development | Signal Transduction and Targeted Therapy
By screening the single-gene knockout library of E. coli, we found that the mutations in other genes related to SOS response, recC, ruvA and uvrD, also cause defective persistence under the induction of rifampicin and tetracycline.42 Moreover, activation of the SOS response increases the frequency of SCVs, a special type of persisters, in S. aureus.302 These findings indicate that SOS response and DNA repair participate in the formation and survival of persisters (Fig.
- Rapid determination of antibiotic susceptibility of clinical isolates of Escherichia coli by SYBR green I/Propidium iodide assay | Scientific Reports
On the other hand, it has been demonstrated that this method can rapidly identify antibiotic susceptibility phenotype in just 60 min for representative clinically important bacterial pathogens, including Staphylococcus aureus, Escherichia coli, ...
- Genome wide analyses reveal the role of mutator phenotypes in Mycobacterium tuberculosis drug resistance emergence | npj Antimicrobials and Resistance
In Pseudomonas aeruginosa, Staphylococcus aureus, and Haemophilus influenzae infections in cystic fibrosis patients, mutators arise due to DNA repair deficiencies, leading to positive selection9,10,11. Similarly, Escherichia coli mutator strains frequently exhibit mismatch repair (MMR) deficiencies12. In Mycobacterium leprae, resistance mutations in hyper-mutator strains are linked to loss-of-function variants of the endonuclease Nth, a key enzyme in Base Excision Repair (BER)13.
- Bacterial Pneumonia - StatPearls - NCBI Bookshelf - NIH
These may include Klebsiella pneumoniae, Legionella species, M pneumoniae, Chlamydia species, Pseudomonas aeruginosa, and in some areas of the world, Mycobacterium tuberculosis and Burkholderia pseudomallei.[13] Escherichia coli, Proteus mirabilis, and other gram-negative coliform bacteria may be associated with aspiration events.[14] Bordetella pertussis may be relevant in unvaccinated populations. Bacterial pathogens in HAP and HCAP globally include K pneumoniae, E coli, P aeruginosa, S aureus, including methicillin-resistant S aureus (MRSA), Enterobacter species, and Acinetobacter baumannii
- Antimicrobial Susceptibility Testing - StatPearls - NCBI Bookshelf
A unique impact of antimicrobial susceptibility testing on patient care is identifying the specific diagnosis and targeting the particular etiologic agent causing the disease. No 2 patients have the same care plan, especially if they have the same signs and symptoms but different treatment regimens because the same causative organism can have different resistance patterns.[22] For example, 2 patients may present with an ordinary strain of Staphylococcus aureus vs methicillin-resistant Staphylococcus aureus (MRSA).
- Classification - Medical Microbiology - NCBI Bookshelf - NIH
Serotyping is also sometimes used to distinguish strains of exceptional virulence or public health importance, for example with V. cholerae (O1 is the pandemic strain) and E. coli (enterotoxigenic, enteroinvasive, enterohemorrhagic, and enteropathogenic serotypes). Phage typing (determining ...
- Antibacterial Susceptibility Test Interpretive Criteria | FDA
The table below lists antibacterial drugs and indicates which, if any, susceptibility test interpretive criteria, also known as “breakpoints” (abbreviated as STIC), are recognized or identified by FDA for that drug. Unless specific exceptions and additions are identified in the table, FDA fully recognizes the standards published in: